Immutep Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma Treatment

Key Facts

1The US FDA granted Orphan Drug Designation to eftilagimod alfa for the treatment of Soft Tissue Sarcoma (STS).

2The drug targets a rare cancer with significant unmet medical needs.

Immutep Limited announced that the US FDA has granted Orphan Drug Designation to its lead product candidate, eftilagimod alfa, for the treatment of Soft Tissue Sarcoma (STS). This designation targets a rare form of cancer where significant unmet medical needs persist. The Orphan Drug status provides Immutep with substantial incentives, including tax credits for clinical trials and seven years of market exclusivity upon regulatory approval. This milestone underscores the therapeutic potential of eftilagimod alfa in addressing rare oncological conditions. The development is viewed as a significant positive catalyst for the clinical-stage biotech company's valuation. Investors are closely monitoring the impact on IMMP and IMM.AX shares following this regulatory breakthrough.